Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial
Blood Cells, Molecules, and Diseases · 2025
DOI: 10.1016/j.bcmd.2025.102936 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Blood Cells, Molecules, and Diseases, 2025. Verfasst von Inayat Ur Rahman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, Khyber Medical University, Peshawar, Pakistan; Department of Pharmacology, Saidu College of Dentistry, Saidu Sh…. Hauptthemen laut MEDLINE: beta-Thalassemia, Gene Expression Regulation, Hematopoiesis, Hemoglobins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACGROUND: Transfusion-dependent β-thalassemia (TDT) requires regular transfusions, often causing iron overload and organ damage. Thalidomide, a fetal hemoglobin (HbF) inducer, may reduce transfusion needs, but scientific data are limited. METHODS: This two-arm, non-randomized clinical trial followed a total of 164 TDT patients over 30 months: 72 received thalidomide and 92 underwent standard transfusions. Complete blood count was assessed at baseline and 6, 12, 18, 24, and 30 months. SNP genotyping and β-globin mutation analysis were performed using sanger sequencing. GATA-1 and KLF gene expression were assessed at baseline and after 30 months via qRT-PCR RESULTS: Hemoglobin level in the thalidomide group significantly increased from 6.12 ± 0.65 g/dL to 8.36 ± 2.04 g/dL (p 12 months and those carrying the minor allele C at HBS1L-MYB rs9399137 (p < 0.05) CONCLUSION: Thalidomide effectively increases hemoglobin levels and reduces transfusion needs in TDT patients, particularly through upregulation of GATA-1 and KLF. AFT and SNP genotype at HBS1L-MYB rs9399137 may help predict response TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT06146478.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Sciences, Khyber Medical University, Peshawar, Pakistan; Department of Pharmacology, Saidu College of Dentistry, Saidu Sharif, Swat, Pakistan.
- Department of Pathology, Pak International Medical College, Peshawar, Pakistan.
- Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
- Institute of Pharmaceutical Sciences, Khyber Medical University, Peshawar, Pakistan; Department of Pharmacology, KMU Institute of Dental Sciences, Kohat, Pakistan.
- Institute of Pharmaceutical Sciences, Khyber Medical University, Peshawar, Pakistan.
- Department of Pharmacology, Peshawar Medical College, Peshawar, Pakistan.
Zitieren
APA
Rahman, I. U., Khan, M. T. M., Ali, Z., Ahmad, S., Shahid, M., Zafar, S., Aamir, F. F., Khan, I., Ali, M., Jelani, M., Khan, K., Ahmad, N., Yousafzai, Y., Mian, A. A., & Siraj, S. (2025). Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial. Blood Cells, Molecules, and Diseases. https://doi.org/10.1016/j.bcmd.2025.102936
Vancouver
Rahman IU, Khan MTM, Ali Z, Ahmad S, Shahid M, Zafar S, et al. Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial. Blood Cells, Molecules, and Diseases. 2025. doi:10.1016/j.bcmd.2025.102936
BibTeX
@article{Rahman2025,
author = {Rahman, Inayat Ur and Khan, Muhammad Tariq Masood and Ali, Zahid and Ahmad, Shafiq and Shahid, Muhammad and Zafar, Shafaq and Aamir, Faheela Faizi and Khan, Imran and Ali, Muhammad and Jelani, Musharraf and Khan, Khalid and Ahmad, Nafees and Yousafzai, Yasar and Mian, Afsar Ali and Siraj, Sami},
title = {Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial},
journal = {Blood Cells, Molecules, and Diseases},
year = {2025},
doi = {10.1016/j.bcmd.2025.102936}
}
EUVIMED